Table 2 Clinical characteristics of infant AML patients undergoing allo-HSCT.
Clinical characteristics | PB ± BM Group (Group 1) | UCB Group (Group 2) | ||
|---|---|---|---|---|
Bu/Cy regimen (plan A + B) | PTCy regimen (plan C + D) | Ex Vivo T-cell depletion (plan E) | Plan F + G | |
Cases | 4 | 10 | 2 | 12 |
Male/female | 3/1 | 6/4 | 1/1 | 9/3 |
HLA match status (n) | Haploidentical (2) Sibling HLA 10/10 match (2) | Haploidentical (9) Sibling HLA 10/10 match (1) | Haploidentical (2) | Unrelated doner with HLA 10/10 match (1), 9/10 (6), 8/10 (4) |
Pre-transplant status (n) | CR1 MRD- (3) NR-7.6% (1) | CR1 MRD- (6) CR2 MRD- (1) CR1 MRD + (3) | CR1 MRD- (2) | CR1 MRD- (7) CR2 MRD- (1) CR1 MRD + (1) NR 5% < MRD < 15% (3) |
Transplant complications (n) | aGVHD (grade III) (1) Pancytopenia (1) Engraftment syndrome (1) | aGVHD (grade I–II) (3) aGVHD (grade III-IV) (2) Hemolytic anemia (1) Secondary thrombocytopenia (1) TMA (1) | aGVHD (grade I) (1) aGVHD (grade III) with pancytopenia, interstitial pneumonia and the following infections (1) | aGVHD (grade I–II) (4) aGVHD (grade III–IV) (1) Hemolytic anemia (1) Secondary thrombocytopenia (1) TMA with pulmonary hemorrhage (1) VOD (2) Engraftment syndrome (1) |
Infections | Sepsis (1) CMV viremia (2) EBV viremia (1) | Sepsis (3) CMV viremia (6) EBV viremia (1) Pulmonary infection (1) Gastrointestinal infection (1) Vasculitis and tissue infection (1) | Intestinal infection, gastrointestinal bleeding, CMV viremia, CMV retinitis (1) | Sepsis (4) CMV viremia (5) Intestinal infection (2) Laryngitis (1) |
Infused MNC (TNC) Cells (Median in × 108/kg) | 10.55 (7.6–29.57) | 16.07 (13.4–23.42) | 45.10 (40.14–50.07) | 1.09 (0.51–2.27) |
Infused CD34 + Cells (Median in × 106/kg) | 3.45 (3.03–27.9) | 8.24 (3.66–16.09) | 25.07 (12.93–37.22) | 0.447 (0.139–1.57) |
Median time to white cell engraftment (days) | 12 (11–16) | 14 (13–23) | 12 (12–13) | 13 (9–18) |
Median time to platelet engraftment (days) | 14 (8–16) | 14 (9–47) | 10 (9–11) | 30 (10–73) |
Post-transplant relapse | 2 | 1 | 0 | 2 |
Survival cases (n) | 2 | 10 | 2 | 11 |
